NEW YORK (360Dx) – Abionic said today that it closed a CHF20 million ($21.1 million) Series C financing round for use in extending its portfolio of point-of-care IVD tests for critical care and emergency medicine.
The firm is preparing to launch a multinational sepsis impact study for its pancreatic stone protein (PSP) test for sepsis risk assessment and management. The test gives an indication of sepsis within five minutes and could be used in emergency departments for risk stratification and to help clinicians decide whether to start antibiotic treatment, Abionic said.
The firm noted that the sepsis impact study will evaluate the efficacy of the PSP test to help clinicians identify sepsis earlier and better manage those at risk of sepsis and septic shock. They will evaluate the test on more than 300 patients in 14 intensive care unit sites in Switzerland, Italy, France, and the United Kingdom.
Bruno François, head of the intensive care unit at the University Hospital of Limoges in France and the principal investigator of the study, said that Abionic’s PSP test has the potential to provide earlier detection of septic patients than is possible with currently available technologies. The real-time diagnosis tool is essential for doctors in starting antibiotic treatment and sepsis resuscitation to improve patient outcomes, he added.
Pierangelo Bottinelli, chairman of Symphony International Holdings, led the round of financing. Also participating were Philippe Glatz, chairman of two private hospitals; Peter Brabeck-Letmathe, former CEO and chairman of Nestlé; Arkady Volozh, cofounder and CEO of Yandex; Jean-Bernard and Nelson Dumas, owners of Dumas Construction; Investiere; and Zürcher Kantonalbank.